Novel Biomarkers in Patients With Acute Myocardial Infarction
NCT ID: NCT05791916
Last Updated: 2024-02-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
500 participants
OBSERVATIONAL
2022-03-10
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Novel Echocardiographic Biomarkers Assessing the Myocardial Work in Heart Failure
NCT05573997
Biomarkers in Acute Cardiac Care
NCT02355457
Biomarkers Predicting Acute Myocardial Infraction in Patients Without Standard Modifiable Risk Factors
NCT05535582
Assessment of New Biomarkers in the Management and Triage of Patients With Chest Pain and Suspicion of Non ST Elevation Acute Coronary Syndrome.
NCT00769574
Risk Stratification Value of Biomarkers in Patients With Myocarditis
NCT06010199
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Following revascularization, a complete and comprehensive medical interview will be conducted for each patient, during which demographic characteristics, baseline medical history, medical therapy upon admission and discharge, primary aetiology, and clinical presentation of hospitalization will be recorded. Laboratory data will be collected on admission and during hospitalization, including complete blood count, biochemical control, coagulation mechanism control, hormonal control, lipid profile including Lp(a), HbA1c, N-terminal pro-B-type natriuretic peptide plasma, higher-peak value of HsTnT, IL-6, and suPAR levels on admission.
A comprehensive transthoracic echocardiographic assessment (TTE) will be performed within 24-48 hours from revascularization to evaluate the cardiac function of patients. The TTE will include 2-dimensional-speckle-tracking analysis of all cardiac chambers and non-invasive calculation of myocardial work of the left and right ventricles. The clinical value and prognostic implications of these echocardiographic indices will also be investigated during follow-up.
The primary objective is to identify novel prognostic tools by examining the association between echocardiographic indices, clinical, and biochemical data. The study aims to contribute to a better understanding of the pathophysiology of this condition and the development of effective management strategies. By comprehensively assessing the clinical, biochemical, and echocardiographic features of patients with AMI, this study will help to establish a foundation for developing targeted and effective treatments for AMI patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients acutely admitted at the Department of Cardiology of AHEPA University General Hospital, Thessaloniki, Greece with Acute Myocardial Infarction, as those are defined by the Fourth Universal Definition of Myocardial Infarction.
3. Patients without known history of coronary artery disease
Exclusion Criteria
2. Patients with a previous history of coronary artery disease and/or prior revascularization
3. Inability or refusal to provide informed consent
4. Subject is pregnant and/or breastfeeding or intends to become pregnant during the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Aristotle University Of Thessaloniki
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Antonios Ziakas, MD, PhD
Role: STUDY_DIRECTOR
School of Medicine, Aristotle University of Thessaloniki
Christos Savopoulos, MD, PhD
Role: STUDY_CHAIR
School of Medicine, Aristotle University of Thessaloniki
Vasileios Kamperidis, MD, MSc, PhD
Role: PRINCIPAL_INVESTIGATOR
School of Medicine, Aristotle University of Thessaloniki
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AHEPA University Hospital, Thessaloniki, Greece
Thessaloniki, Central Macedonia, Greece
AHEPA University Hospital, Thessaloniki, Greece
Thessaloniki, Central Macedonia, Greece
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Daios S, Anastasiou V, Moysidis DV, Didagelos M, Papazoglou AS, Stalikas N, Zegkos T, Karagiannidis E, Skoura L, Kaiafa G, Makedou K, Ziakas A, Savopoulos C, Kamperidis V. Prognostic Implications of Clinical, Laboratory and Echocardiographic Biomarkers in Patients with Acute Myocardial Infarction-Rationale and Design of the ''CLEAR-AMI Study''. J Clin Med. 2023 Sep 2;12(17):5726. doi: 10.3390/jcm12175726.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3456/20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.